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Keratoconus is a common corneal ectatic disorder which affects 
approximately 1 in 2,000 people. The traditional treatments for 
keratoconus are the use of inserts, deep anterior lamellar kerato-
plasty (DALK) and anterior lamellar keratoplasty (ALKP). Corneal 
cross-Linking is a relatively new minimally invasive therapeutic
approach for treatment of progressive keratoconus, which increases 
the structural integrity of the cornea. In corneal cross-linking the
production of oxygen free radicals by ultraviolet A (UVA) light
increases the biomechanical strength of cornea while riboflavin 
acts as a photo synthesizer for production of oxygen free radicals by 
UVA. Treatment of progressive keratoconus is the most widespread 
use of cross-linking technique. In the present manuscript we will
summarize different aspects of the utilization of cross-linking in
treatment of corneal keratoconus. 
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Introduction
Keratoconus is a relatively common corneal 
ectatic disorder which affects approximately 1 
in 2,000 people 1,2. It usually develops among 
young adults 3. This disease is characterized 
by a cone-shaped thin cornea which leads 
to vision impairment by causing myopia 
and irregular astigmatism 4,5. The previous 
treatments for keratoconus were the use 
of inserts or corneal grafts 6 as well as deep 
anterior lamellar keratoplasty (DALK) and 
anterior lamellar keratoplasty (ALKP) 7. In 
recent years, a new minimally invasive thera-
peutic approach, called corneal cross-linking, 
has been proposed for the treatment of these 
patients 7,8. Early in vitro studies by Spörl et 
al., 9 in 1997 evaluated the potential of us-
ing a combination of riboflavin (vitamin B2) 
and ultraviolet type A light in treatment of
keratoconus leading to advent of corne-
al cross-linking. Corneal cross-linking is a 
relatively safe procedure with minimal or no 
endothelial cell damage 10. It also does not 
cause loss of corneal transparency or damage 
to deeper ocular structures 10-12. This method 
is the first available therapeutic approach 
to increase corneal resistance, which might 
stop or even reverse the progression of the 
disease in people with keratoconus 13. In the 
present manuscript we will summarize different 
aspects of the utilization of cross-linking in 
treatment of corneal keratoconus. 
Mechanism of Action
Corneal collagen cross-linking is a treatment 
which increases the structural integrity of the 
cornea 14. The production of oxygen free radicals 
by ultraviolet A (UVA) light in cross-linking in-
creases the biomechanical strength of cornea and 
its resistance to enzymatic degradation by creating 
cross-links between collagen molecules in corneal 
stroma and strengthening the interlamellar collagen 
fibril adhesion of adjacent lamellae originally 
weakened by keratoconus 11, 15, 16. In this process 
riboflavin acts as a photo synthesizer for pro-
duction of oxygen free radicals by UVA and also 
prevents damage to deeper ocular structures by 
absorbing the UVA irradiation 16.
Cross-linking has a variety of other implemen-
tations like in polymer industry to increase the 
strength of polymers, in dentistry to increase 
the strength of filling material and in pathology 
to preserve tissue samples 17. This process also
occurs in the natural process of tissue aging, which 
is referred to as physiological cross-linking 18. The 
cross-linking phenomenon occurs with a higher 
rate than normal among smokers as well as in 
people with diabetes mellitus, which can justify 
premature aging among these people 19, 20.
Indications 
Treatment of progressive keratoconus is the 
most widespread indication of cross-linking 21. 
It should be noted that documented evidence 
of progression of the keratoconus is necessary 
before performing cross-linking 22. It can also 
be used in patients with post-LASIK ectasia 
22, borderline endothelial function such as cor-
neal guttata 20, as well as bullous keratopathy 
23, 24 and keratectasia caused by laser in situ 
keratomileusis 25, pellucid marginal degenera-
tion (PMD) and iatrogenic ectasia 26. Corneal 
cross-linking has also been suggested to treat 
patients with infectious keratitis 27-29. 
Contraindications 
It was believed that corneal cross-linking 
should be avoided in corneas with corne-
al thickness of less than 400 µm 11. Efforts 
have been made to modify the cross-linking
procedure to be applicable in thin corneas; 
however the evidence of safety and efficacy in 
the use of modified cross-linking protocols for 
thinner corneas is still limited to few studies 11.
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Relative contraindications are maximum K 
reading of more than 58.00 D 11, IOP over 21 
mmhg, a history of glaucoma, corneal guttata 
or other endothelial irregularities, a history 
of recurrent erosions, ocular surface disorders, 
and connective tissue diseases 6. Treatment 
during pregnancy should be deferred as the 
safety of the procedure and its impact to the
fetus has not been established 12. Another relative 
contraindication is extensive corneal scarring 12. 
Concurrent ocular infection, neurotrophic
keratopathy, past history of poor epitheli-
al wound healing, severe dry eye, are also
considered contraindication for cross-linking 12.
Complications
Permanent loss of 2 or more Snellen lines might 
happen in about 1 to 3 % of patients 30. Age 
older than 35 years and a preoperative CDVA 
of better than 20/25 have been indicated as
significant risk factors for complications 30. Haze 
might increase immediately after cross-link-
ing but completely subsides in most cases 31. 
Temporary corneal edema and persistent
corneal edema necessitating further treatment 
have been reported in patients undergoing 
corneal cross linking 32. During the epithelial 
healing, the cornea is vulnerable to infection 
and melting and infectious keratitis has been 
reported 33, 34. Also endothelial damage might 
occur if the cross linking procedure is used in 
thin corneas (340–399 μm) 35. 
Outcome of CCL in some recent studies
In a study by Tiveron at al., 36 in 2017 on 
topographic outcomes after performing
corneal cross-linking the authors found that
after 3 months, steepest keratometry read-
ing (K2) and maximum keratometry (Kmax) 
weresignificantly decreased with no statist 
cally significant difference between male and
female patients. In a prospective, randomized,
double-blind trial with average follow-up of 
1098 days by Lang et al., 37 conducted in 2015, 
the efficacy and safety of corneal cross-linking 
for halting the progression of keratoconus were 
investigated. In this study, refractive power on 
average decreased by 0.35 ± 0.58 diopters/
year in treatment group. The controls showed 
an increase of 0.11 ± 0.61 diopters/year 34. The 
difference between the case and control group 
was statistically significant 37. In a study by 
Recalde et al., 38 on variations in tear quantity 
and quality after corneal collagen cross-link-
ing in patients with keratoconus the authors 
found that during the first postoperative year,
corneal cross-linking does not modify the
parameters used to evaluate tear film function. 
Plat et al., 39 in their study on influence of corneal
collagen cross-linking on anterior chamber in
keratoconus found that improvement of
corneal parameters by corneal cross-linking in
keratoconus patients have a positive effect on 
anterior chamber parameters at the 6-month 
postoperative evaluation. Kosekahya et al., 
40 evaluated changes in the coordinates of 
the line of sight and higher order aberrations 
of eyes with keratoconus, following corne-
al crosslinking and found that line of sight
significantly shifts to the nasal region after
corneal corneal cross-linking in both right 
and left eyes and the improvements in HOAs 
are significant at postoperative 6th month
compared to the baseline measurements. 
Ameen et al., 41 in a study to evaluate the
efficacy and safety of transepithelial collagen 
cross-linking in patients with progressive kera-
toconus found statistically significant changes 
from baseline in astigmatism, Maximum simu-
lated Keratometry value (Kmax) and Spherical 
equivalent (SE). They concluded that transep-
ithelial collagen cross-linking is a safe and ef-
fective procedure with statistically significant 
reduction in corneal astigmatism, Kmax and SE, 
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with reasonable gain in Snellen's visual acuity 41. 
Wittig-Silva et al., 42 in analysis of 66 progres-
sive keratoconus patients treated with collagen 
cross-linking reported a flattening (K-max) by 
an average of 0.74 diopters at 3 months, 0.92 
D at 6 months and 1.45 D at 12 months. In the 
control eyes, mean K-max steepened by 0.60 D 
after 3 months, 0.60 D after 6 months, and 1.28 
D after 12 months. No statistically significant 
changes were found for spherical equivalent or 
endothelial cell density. 42 In a study performed 
on Iranian patients by Saffarian et al., 43 in 
2010 the mean baseline simulated keratometry 
(SIM K) was 46.94 ± 2.37 D which decreased 
to 46.0 ± 2.33 D one year postoperatively.
The use of corneal cross-linking in combination 
with other treatment methods
Corneal cross-linking might be used in 
combination with other treatment modal-
ities to optimize visual outcomes in eyes 
with keratoconus 44. Combined use of
cross-linking and photorefractive keratect 
my (PRK) has been suggested. Kymionis 
et al., 45 evaluated the use of customized
topography-guided PRK followed by cor-
neal CXL for treatment of progressive 
keratoconus. They found that at their last
follow-up 16 months post operatively
spherical equivalent and defocus were statisti-
cally significantly reduced to compared to pre 
surgical readings 45. Fadlallah et al., 46 evaluat-
ed the safety and clinical outcome of combined
photorefractive keratectomy (PRK) and corne-
al collagen cross-linking in treatment of mild 
refractive errors in patients with early stage
keratoconus. They reported that UDVA
significantly improved and CDVA remained 
stable. Also the mean spherical equivalent and 
the mean cylinder and mean central corneal 
thickness significantly decreased with no intra-
operative complications 46. Another suggested 
combination therapy is combined cross-linking 
and corneal ICRS insertion 47. Abdelmassih et 
al., 48 evaluated the safety and visual outcomes of 
ICRS implantation followed by cross-linking
in pediatric keratoconus patients. They found 
that ICRS implantation is a safe and effective
procedure for visual rehabilitation in children 
with keratoconus and poor CDVA with no
intraoperative or postoperative complications 48.
In this study at the 6-month follow-up, mean 
CDVA and UDVA showed significant improve-
ment in comparison to preoperative levels and 
a significant decrease in both keratometry 
readings and spherical equivalent was also 
observed 48. 
The early detection and proper management 
of patients with keratoconus using minimally
invasive therapeutic approaches like corne-
al cross linking will improve the quality of 
life among these patients and might delay 
or eliminate the need for subsequent corneal
transplantation 49.
Conclusion
A strong body of literature suggests that
corneal cross-linking is an effective and safe
treatment method for halting the progression of
keratoconus. Future studies should focus on 
the long term results and improvements in 
methodology of this technique.
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